Admelog (insulin lispro) NDC 70518-4275

NDC codes

FDA NDC Directory

Product NDC (as listed)70518-4275Labeler and product segments. Claims need a package NDC.

Product NDC at billing width70518-4275Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
70518-4275-0	70518427500	5 SYRINGE in 1 CARTON (70518-4275-0) / 3 mL in 1 SYRINGEMarketed from Feb 4, 2025

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Admelog
Generic name (nonproprietary): insulin lispro
Active ingredients: Insulin lispro — 100 U/mL
Dosage form: Injection, Solution
Route: Subcutaneous
Labeler: REMEDYREPACK INC.
Product type: Prescription drug
Marketing category: BLA — Biologics License ApplicationApplication BLA 209196
Marketing start: Feb 4, 2025
Listing expires: Dec 31, 2027
Other FDA classes: Insulin (Chemical/Ingredient)
Identifiers: Product ID 70518-4275_5a947dc5-7059-82ab-e063-6394a90af352SPL ID 5a947dc5-7059-82ab-e063-6394a90af352SPL set ID 12ec9e3f-e2ac-43a1-b334-8b6538cf2bb0RxCUI 1652639, 1992171UNII GFX7QIS1II
Pharmacologic class: Insulin Analog

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N470518427500 followed by a unit qualifier and the quantity

Package 70518-4275-00. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Sep 3, 2026.

Indications (excerpt from the label)

ADMELOG is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. ADMELOG is a rapid-acting human insulin analog indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under BLA 209196

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under BLA 209196
Product	Strength	Form · route	Labeler	Product NDC
Admeloginsulin lispro	Insulin lispro 100 U/mL	Injection, SolutionIntravenous, Subcutaneous	Sanofi-Aventis U.S. LLC	0024-5926
Admeloginsulin lispro	Insulin lispro 100 U/mL	Injection, SolutionIntravenous, Subcutaneous	Sanofi-Aventis U.S. LLC	0024-5924
Admeloginsulin lispro	Insulin lispro 100 U/mL	Injection, SolutionSubcutaneous	Sanofi-Aventis U.S. LLC	0024-5925